Lorenzo M. Tallarigo
Director/Board Member chez University of Indianapolis
Profil
Lorenzo M.
Tallarigo is on the board of the University of Indianapolis, Angelini Holding SRL and Angelini Holding SpA.
He previously was Independent Director at Intercept Pharmaceuticals, Inc., Non-Executive Chairman of Oxford Biomedica Plc, Chairman for EryDel SpA, Chairman of Tethis SpA, President-Intercontinental Operations at Eli Lilly & Co. and Chief Executive Officer & Director at Genextra SpA.
Dr. Tallarigo received a doctorate from the University of Pisa and a doctorate from Harvard Business School.
Postes actifs de Lorenzo M. Tallarigo
Sociétés | Poste | Début |
---|---|---|
University of Indianapolis | Director/Board Member | 05/08/2009 |
Angelini Holding SRL | Director/Board Member | 01/01/2019 |
Angelini Holding SpA
Angelini Holding SpA Financial ConglomeratesFinance Angelini Holding SpA is a private company based in Italy that operates under the umbrella of Angelini Industries. Angelini Industries is a diversified group with various business interests. Angelini Holding has subsidiaries in Italy. The Italian company was founded in 1919 by Francesco Angelini, and Sergio Marullo di Condojanni has been the CEO of the company since 2019. | Director/Board Member | 01/01/2019 |
Anciens postes connus de Lorenzo M. Tallarigo
Sociétés | Poste | Fin |
---|---|---|
OXFORD BIOMEDICA PLC | Chairman | 23/06/2020 |
INTERCEPT PHARMACEUTICALS, INC. | Chairman | 18/10/2013 |
ELI LILLY AND COMPANY | Chief Operating Officer | - |
EryDel SpA
EryDel SpA Medical SpecialtiesHealth Technology EryDel SpA offers medical research. It develops drugs and diagnostics delivered through human red blood cells via a medical device technology. The company was founded by Luigia Rossi and Mauro Magnani in 2007 and is headquartered in Bresso, Italy. | Chairman | - |
Tethis SpA
Tethis SpA BiotechnologyHealth Technology Tethis SpA engages in the provision of nanobiotechnology solutions. It develops devices for liquid biopsy, molecular diagnostic, and proteomic and microbiology. The company was founded by Emanuele Barborini, Simone Vinati, and Massimo Gatelli in 2004 and is headquartered in Milan Italy. | Chairman | - |
Formation de Lorenzo M. Tallarigo
University of Pisa | Doctorate Degree |
Harvard Business School | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 3 |
---|---|
ELI LILLY AND COMPANY | Health Technology |
INTERCEPT PHARMACEUTICALS, INC. | Health Technology |
OXFORD BIOMEDICA PLC | Health Technology |
Entreprise privées | 5 |
---|---|
Genextra SpA
Genextra SpA Investment ManagersFinance Genextra SpA (Genextra) is a venture capital firm founded in 2004 by Franceso Micheli and Saverio Minucci. The firm is headquartered in Milan, Italy. | Finance |
EryDel SpA
EryDel SpA Medical SpecialtiesHealth Technology EryDel SpA offers medical research. It develops drugs and diagnostics delivered through human red blood cells via a medical device technology. The company was founded by Luigia Rossi and Mauro Magnani in 2007 and is headquartered in Bresso, Italy. | Health Technology |
Tethis SpA
Tethis SpA BiotechnologyHealth Technology Tethis SpA engages in the provision of nanobiotechnology solutions. It develops devices for liquid biopsy, molecular diagnostic, and proteomic and microbiology. The company was founded by Emanuele Barborini, Simone Vinati, and Massimo Gatelli in 2004 and is headquartered in Milan Italy. | Health Technology |
Angelini Holding SRL | |
Angelini Holding SpA
Angelini Holding SpA Financial ConglomeratesFinance Angelini Holding SpA is a private company based in Italy that operates under the umbrella of Angelini Industries. Angelini Industries is a diversified group with various business interests. Angelini Holding has subsidiaries in Italy. The Italian company was founded in 1919 by Francesco Angelini, and Sergio Marullo di Condojanni has been the CEO of the company since 2019. | Finance |